Update on the Role of Somatostatin Analogs for the Treatment of Patients With Gastroenteropancreatic Neuroendocrine Tumors
- 28 February 2013
- journal article
- review article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 40 (1), 56-68
- https://doi.org/10.1053/j.seminoncol.2012.11.006
Abstract
No abstract availableKeywords
This publication has 92 references indexed in Scilit:
- PLGA Nanoparticles for Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Novel Approach towards Reduction of Renal Radiation DosePLOS ONE, 2012
- Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)Gut, 2011
- Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)Alimentary Pharmacology & Therapeutics, 2011
- NANETS Treatment GuidelinesPancreas, 2010
- 90Y-Edotreotide for Metastatic Carcinoid Refractory to OctreotideJournal of Clinical Oncology, 2010
- Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectivesJournal of Experimental & Clinical Cancer Research, 2010
- Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine TumorsGastroenterology, 2008
- Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Radiolabeled somatostatin receptor antagonists are preferable to agonists forin vivopeptide receptor targeting of tumorsProceedings of the National Academy of Sciences of the United States of America, 2006
- Treatment of the Malignant Carcinoid SyndromeThe New England Journal of Medicine, 1986